Holen Sie sich die Stockscreener-App
12.23
6.14%
-0.6089
Schlusskurs vom Vortag:
$12.84
Offen:
$12.77
24-Stunden-Volumen:
973.67K
Relative Volume:
0.83
Marktkapitalisierung:
$647.68M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.8287
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
+23.73%
1M Leistung:
+36.63%
6M Leistung:
+125.68%
1J Leistung:
+33.02%
1-Tages-Spanne:
$11.74
$13.00
1-Wochen-Bereich:
$9.21
$13.41
52-Wochen-Spanne:
$4.02
$13.41
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.14 | 676.67M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
143.02 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.43 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.245 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.09 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.03 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Is Emergent BioSolutions Inc. stock dividend yield sustainableJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
What sentiment indicators say about Emergent BioSolutions Inc. stock2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
symbol__ Stock Quote Price and Forecast - CNN
How Emergent BioSolutions Inc. stock benefits from tech adoptionJuly 2025 Momentum & Verified Momentum Watchlists - newser.com
Why Emergent BioSolutions Inc. (ER4) stock is trending on social media2025 Historical Comparison & Advanced Swing Trade Entry Plans - newser.com
Emergent BioSolutions Reports Strong Q3 2025 Results - The Globe and Mail
Why Emergent BioSolutions Inc. (ER4) stock is listed among top recommendations2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Will Emergent BioSolutions Inc. stock return to pre crisis levelsPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results, Beats Expectations By $1.18 EPS - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Emergent BioSolutions (EBS) Earnings Transcript - The Globe and Mail
Emergent BioSolutions Inc (EBS) Q3 2025 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge - MSN
Gaithersburg-based Emergent Biosolutions reports Q3 earnings - Maryland Daily Record
Analyzing Emergent BioSolutions Inc. with multi timeframe chartsQuarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Will Emergent BioSolutions Inc. benefit from macro trendsBull Run & Reliable Volume Spike Trade Alerts - newser.com
Will Emergent BioSolutions Inc. stock sustain high P E ratiosJuly 2025 Gainers & Precise Buy Zone Identification - newser.com
Why Emergent BioSolutions Inc. (ER4) stock remains top ratedMarket Growth Summary & Verified Entry Point Signals - newser.com
Emergent Biosolutions: Q3 Earnings Snapshot - Stamford Advocate
Understanding Emergent BioSolutions Inc.’s price movementWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Will breakout in Emergent BioSolutions Inc. lead to full recoveryEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Why millennials buy Emergent BioSolutions Inc. (ER4) stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Reversal indicators forming on Emergent BioSolutions Inc. stockJuly 2025 Update & Safe Entry Zone Identification - newser.com
Is Emergent BioSolutions Inc. a candidate for recovery playGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Emergent Biosolutions earnings beat by $1.01, revenue topped estimates - Investing.com Canada
Why Emergent BioSolutions Inc. stock remains resilientJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates - sharewise.com
EBS Boosts Financial Outlook for Fiscal Year - GuruFocus
Emergent BioSolutions Inc Bottom Line Drops In Q3 - Nasdaq
Emergent BioSolutions Raises Full-Year Revenue Guidance - TipRanks
Emergent BioSolutions Inc Reports Q3 2025 Earnings: EPS of $0.91 - GuruFocus
Emergent BioSolutions Q3 revenue beats guidance, raises full-year outlook - TradingView
Emergent BioSolutions Reports Third Quarter 2025 Financial Results - The Manila Times
How Emergent BioSolutions Inc. (ER4) stock behaves in tightening cyclesJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Investors in Emergent BioSolutions (NYSE:EBS) have unfortunately lost 90% over the last five years - Yahoo Finance
Chart based exit strategy for Emergent BioSolutions Inc.Watch List & High Accuracy Investment Entry Signals - newser.com
Why Emergent BioSolutions Inc. stock could rally in 20252025 Short Interest & Growth Oriented Trading Recommendations - newser.com
Emergent Biosolutions Q3 earnings call set to reveal financial results - Traders Union
Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit - Stocktwits
Emergent (NYSE: EBS): 45% say U.S. unprepared, 65% see rising bioattack risk - Stock Titan
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.78%
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):